What Researchers Did
Researchers tested the safety of Dexcom G6 continuous glucose monitoring (CGM) transmitters during hyperbaric oxygen therapy (HBOT) by subjecting six devices to 11 pressurization cycles up to 45 feet of seawater.
What They Found
The study found no changes in estimated glucose value generator readings or structural damage to the six Dexcom G6 CGM transmitters after 11 hyperbaric exposures to 45 feet of seawater. This means the transmitters meet the 2018 National Fire Protection Association 99 safety requirements for battery-operated devices allowed for use in a hyperbaric environment.
Canadian Relevance
This study covers a Health Canada-recognised indication, as hyperbaric oxygen therapy is used for diabetic foot ulcers, and this research addresses the safety of glucose monitoring for diabetic patients undergoing HBOT.
Study Limitations
This study focused on a specific continuous glucose monitoring device, the Dexcom G6, and a limited number of test cycles.